Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Biol Psychiatry. 2017 Jun 23;83(1):29–37. doi: 10.1016/j.biopsych.2017.06.017

Figure 4. VU0255035 stimulates BDNF release and phospho-ERK signaling in primary neuronal cultures.

Figure 4

(A, B) Similar to scopolamine, incubation with a selective M1-AChR antagonist VU0255035 increased in (pERK) and phospho-S6K (pS6K) levels in a concentration dependent manner. (C) VU0255035 incubation (3 nM) also increased BDNF release into the media, and preincubation with TTX (50 μM, 20 min) prior completely blocked this effect. TTX alone had no effect on BDNF release (main effect of scopolamine (F1, 12 = 5.57, *p<0.05); scopolamine X TTX (F1, 12 = 9.11, *p<0.05)). (D, E) Incubation with CNQX (10 μM) or muscimol (10 μM) also significantly blocked BDNF release induced by scopolamine (main effect of scopolamine, *p<0.05); scopolamine X drug (*p<0.05)). Incubation with muscimol alone significantly decreased BDNF release. All results are presented as mean ± SEM and fold change. *p < 0.05, compared to vehicle. #p < 0.05, compared to scopolamine (n=6/group).